Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Osteoporosis 2Breast Neoplasms 2Polycystic Ovary Syndrome 1Pituitary Neoplasms 1Myocardial Ischemia 1Infertility, Female 1Heart Diseases 1Fractures, Bone 1Coronary Disease 1Colonic Neoplasms 1Cardiovascular Diseases 1Bone Diseases 1

Interventions

pasireotide 7Cabergoline 7Temozolomide 3Propofol 3Hydrocortisone 3Dexmedetomidine 3lanreotide 2Sevoflurane 2Saline Solution 2Rosiglitazone 2Proton Therapy 2Octreotide 2Dexamethasone 2Desflurane 2pegvisomant 1parecoxib 1lutetium Lu 177 dotatate 1loxoprofen 1farletuzumab 1entinostat 1corticorelin ovine 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Trimethoprim 1Transcranial Magnetic Stimulation 1Tranexamic Acid 1Tramadol 1Thyrotropin-Releasing Hormone 1TBR-760 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pituitary Neoplasms × Hormone Replacement Therapy × Clear all
NCT06679816 2025-01-14

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

Beijing Tiantan Hospital

Phase 4 Recruiting
882 enrolled
Endocrine

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡